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Abstract 
The gene for adrenoleukodystrophy (X-ALD), a peroxisomal disease characterized by excessive accumulation f very long-chain (VLC) fatty acids 
(> C22: 07, has recently been identified by positional c oning, and it is predicted toencode a protein (ALD-P) of 745 amino acids [(1993) Nature 361, 
726]. Using Western blot analysis of subcellular o ganelles purified by isopycnic density gradient centrifugation from X-ALD and control fibroblasts, 
we show that he monoclonal antibodies directed against ALD-P cross-react with a 75 kDa protein in intact peroxisomes and that ALD-P is an integral 
component of the peroxisomal membrane. Moreover, no signal for ALD-P was detected in peroxisomes from X-ALD patients with deletion of the 
ALD gene. 
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I. Introduction 
Adrenoleukodystrophy (X-ALD), a peroxisomal dis- 
ease, is an X-linked progressive degenerative neurologi- 
cal disorder affecting the central nervous system and 
adrenal cortex [1 5]. It is associated with the pathogno- 
monic accumulation of saturated very long-chain (VLC) 
fatty acids (> C22) as a constituent of cholesterol esters, 
phospholipids and gangliosides [3-5]. Although X-ALD 
presents as various clinical phenotypes, including child- 
hood X-ALD, adrenomyeloneuropathy (AMN), and 
Addison's disease, all forms of X-ALD accumulate VLC 
fatty acids at similar concentrations in fibroblasts and 
plasma [4,5]. The increased levels of VLC fatty acids has 
been used as a diagnostic tool both in prenatal and post- 
natal diagnosis [1,4-6]. 
To delineate the specific enzyme defect, initial studies 
focused on the metabolism of cholesterol esters since 
there is excessive accumulation of VLC fatty acids in the 
cholesterol ester fraction. However, no defect was ob- 
served [7,8]. The accumulation of VLC fatty acids in 
lipids other than cholesterol esters [4-6] and normal me- 
tabolism of cholesterol esters uggested that the defect in 
X-ALD may be in the metabolism of VLC fatty acids. 
A number of laboratories, including ours, showed that 
oxidation of VLC fatty acids is deficient in X-ALD cul- 
tured skin fibroblasts, whereas oxidation of palmitic acid 
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is normal [7,9-13]. The identification of peroxisomes as 
the site of oxidation of VLC fatty acids [10] suggested 
that X-ALD might be a peroxisomal disease. Direct 
demonstration f defective oxidation of VLC fatty acids 
in peroxisomes i olated from cultured X-ALD skin fi- 
broblasts established that X-ALD is a disease associated 
with a defect in the peroxisomal fl-oxidation system [14]. 
The deficient oxidation of free lignoceric acid (sub- 
strate for the first step in the oxidation of fatty acids) as 
compared to the normal oxidation of lignoceroyl-CoA 
and ~-,fl-unsaturated lignoceroyl-CoA (substrates for 
the 2nd and 3rd step in the fl-oxidation of fatty acids) 
suggested that the abnormality in oxidation of VLC fatty 
acids (lignoceric acid) may be due to deficient activity of 
lignoceroyl-CoA ligase required for the activation of lig- 
noceric acid to lignoceroyl-CoA [12,15]. The deficient 
activity of lignoceroyl-CoA ligase as compared to the 
normal oxidation of lignoceroyl-CoA in purified per- 
oxisomes upported this conclusion [14,17]. These obser- 
vations suggested that the gene coding for lignoceroyl- 
CoA ligase may be a candidate for the X-ALD gene; 
however, the recent identification of the ALD gene by 
positional cloning [18-20] led to a different conclusion. 
The protein sequence ncoded by this gene (ALD-P) has 
significant homology with the 70 kDa peroxisomal mem- 
brane protein [18,21], a member of the ATP-binding cas- 
sette (ABC) superfamily of the transporters [22]. This 
suggests that ALD-P could be responsible for incorpora- 
tion of lignoceroyl-CoA ligase in the membranes of per- 
oxisomes [18]. However, the levels of mRNA for the 
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ALD gene did not correlate with the amount of per- 
oxisomes in various organs [18]. For example, the 
amount of peroxisomes in liver are relatively much 
higher as compared to muscle, but the muscle contained 
higher amounts of mRNA compared to liver. This raised 
the question of whether the protein transcribed by the 
ALD gene is in fact a peroxisomal component. To an- 
swer this question we used monoclonal antibodies raised 
against ALD-P [23] to determine its distribution in vari- 
ous subcellular organelles purified by the isopycnic den- 
sity gradient technique from control and cell lines from 
patients with deletion of the ALD gene. 
2. Experimental 
The subcellular organelles were prepared by isopycnic density gradi- 
ent centrifugation in Nycodenz (Accurate Chemical and Scientific 
Corp., Westbury, NY) from cultured skin fibroblasts from controls and 
X-ALD patients as described previously [14]. Thirty or more confluent 
flasks (75 cm*) of cultured skin fibroblasts from control and X-ALD 
patients were harvested, cell pellets were washed with homogenizing 
medium (0.25 M sucrose, 1 mM EDTA, 0.5pg/ml of antipain, 0.5,&ml 
of leupeptin, 1 &ml of aprotinin, 0.7 &ml pepstatin, 0.2 mM phen- 
ylmethylsulfonylfluoride, 0.1% ethanol in 3 mM imidazole buffer (pH 
7.4)) at 4°C and the subcellular organelles were purified by differential 
and isopycnic density gradient centrifugation [14]. The gradient was 
collected from the bottom and analyzed by the marker enzyme activities 
of catalase for peroxisomes, NADPH cytochrome c reductase for endo- 
plasmic reticulum and cytochrome c oxidase for mitochondria. The 
purity of peroxisomes was between 90-92% with small concentration 
of mitochondria (5.4 f 2.4%) endoplasmic reticulum (2.2 f 1.2%) and 
lysosomes (0.9 f 0.4%) [25]. The peroxisomal membrane and matrix 
components were prepared by carbonate treatment of the peroxisomal 
peak from the Nycodenz gradient as described previously [24]. Mono- 
clonal antibodies (lD6) raised against protein sequence corresponding 
to codons Leu *79-Va1482 [l&20] were used to detect the ALD-P in vari- 
ous subcellular organelles by Western blot analysis. 
3. Results and discussion 
Fig. 1 shows the subcellular fractionation of cultured 
skin fibroblasts from control (Fig. 1A) and X-ALD (Fig. 
1B). The distribution of activities of catalase for per- 
oxisomes, cytochrome c oxidase for mitochondria and 
NADPH cytochrome c reductase for endoplasmic reticu- 
lum were similar from control and X-ALD cells. The 
peroxisomes were very well resolved from other subcellu- 
lar organelles. This procedure allows us to purify per- 
oxisomes of over 90% purity [25]. The antibodies against 
ALD-P recognized only one protein with an apparent 
molecular mass of 75 kDa in gradient fractions contain- 
ing peroxisomes, as identified with catalase, in control 
cultured skin fibroblasts (Fig. 2). The antibodies against 
ALD-P react with a protein which migrates in SDS- 
PAGE at 75 kDa instead of 83 kDa as expected from the 
coding sequence (Figs. 2 and 3). This difference in elec- 
trophoretic mobility may be due to hydrophobicity, as 
previously observed with the 70 kDa peroxisomal mem- 
brane protein [21]. These results demonstrate that ALD- 
P is a component of peroxisomes. Peroxisomes are made 
of limiting membrane and matrix proteins. 
Next we examined the distribution of ALD-P in per- 
oxisomal membrane and peroxisomal matrix compo- 
nents isolated from purified peroxisomes using the so- 
dium carbonate procedure [24]. This procedure releases 
all the matrix and membrane-associated proteins from 
the peroxisomes and leaves behind membranes contain- 
ing phospholipids and integral proteins [24]. The 
peroxisomal membrane prepared by this procedure rep- 
resents only 12% of the peroxisomal protein with phos- 
pholipid-to-protein ratio of 200 nmol/mg [24]. The anti- 
bodies against ALD-P cross-reacted with a 75 kDa pro- 
tein in peroxisomal membranes, but no signal was de- 
tected in matrix proteins (Fig. 3). To further establish 
that the ALD-P is in fact a component of the per- 
oxisomal membrane, we searched for the presence of the 
ALD-P in different subcellular organelles and per- 
oxisomal membranes and matrix isolated from purified 
peroxisomes (Fig. 3) from X-ALD which were previ- 
ously shown to have a deletion of the X-ALD gene [18] 
and absence of mRNA of the ALD gene [19]. The anti- 
bodies against ALD-P did not recognize any protein in 
peroxisomal membranes or matrix (Fig. 3) or in any of 
the other subcellular organelles in the gradient (data not 
shown here) from X-ALD fibroblasts with a deletion of 
the X-ALD gene. 
The peroxisomal j&oxidation system consists of four 
enzymes: acyl-CoA ligases, acyl-CoA oxidase, trifunc- 
tional enzyme and thiolase. Fatty acids are converted to 
their CoA derivatives in the peroxisomal membrane and 
then transported to the matrix for their oxidation [26]. 
The deficient oxidation of lignoceric acid as compared 
to the normal oxidation of lignoceroyl-CoA in X-ALD 
peroxisomes [ 12,151, the deficient activity of lignoceroyl- 
CoA ligase in peroxisomes isolated from X-ALD [ 14,161, 
and the normalization of oxidation of lignoceric acid 
when peroxisomes from X-ALD were supplemented with 
exogenous lignoceroyl-CoA ligase [ 171, demonstrate that 
the abnormality in the oxidation of VLC fatty acids in 
X-ALD is due to a functional defect in the activity of 
lignoceroyl-CoA ligase present in the peroxisomal mem- 
branes. 
Peroxisomal membranes contain at least three distinct 
acyl-CoA ligases with enzyme activities for palmitic acid 
[27-291, lignoceric acid [28,29] and phytanic acid [30]. 
The active site of palmitoyl-CoA ligase [27-291 and phy- 
tanoyl-CoA ligase [3 l] is on the cytoplasmic surface, and 
that of lignoceroyl-CoA ligase is on the luminal surface 
of the peroxisomal membrane [28]. Consistent with the 
topology of the active site of acyl-CoA ligases, phytanic 
acid [31] and palmitic acid are transported into per- 
oxisomes as acyl-CoA derivatives [3 1,321, whereas ligno- 
ceric acid is transported into peroxisomes as free fatty 
acid and then activated to lignoceroyl-CoA on the lumi- 
nal surface prior to its p-oxidation in the matrix [32]. 
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This implies that CoASH, ATP and lignoceric acid, re- 
quired for synthesis of lignoceroyl-CoA, need to be 
transported into peroxisomes for the activation of ligno- 
ceric acid by lignoceroyl-CoA ligase on the luminal sur- 
face of the peroxisomal membrane. The data reported in 
this manuscript clearly demonstrate that ALD-P is a 
component of the peroxisomal integral membrane. 
Therefore, the abnormality in the degradation of VLC 
fatty acids observed in X-ALD peroxisomes may be the 
result of the absence of or an abnormality in ALD-P in 
peroxisomal membranes. 
Based on the possible function of ALD-P as a trans- 
porter protein, ALD-P may influence the activity of lig- 
noceroyl-CoA ligase by either restricting the entry of 
cofactors required for its activity or as a result of an 
abnormality in the enzyme’s activity. The deficient activ- 
ity of lignoceroyl-CoA ligase in peroxisomes from X- 
ALD may not be due to restricted import of fatty acid 
or nucleotides into peroxisomes because molecules 
smaller than 800 Da (e.g. CoASH and ATP) are freely 
permeable through the non-specific pores present in this 
membrane [33], and no abnormality was observed in the 
transport of lignoceric acid into peroxisomes from X- 
ALD [32]. ALD-P is more likely to be involved in the 
transport of lignoceroyl-CoA ligase or may serve a struc- 
tural function necessary for the activity of lignoceroyl- 
CoA ligase in the peroxisomal membrane. The fact that 
ALD-P could transport lignoceroyl-CoA ligase is ques- 
tionable at least for two reasons; first, if we assume that 
ALD-P is indeed a transporter, it would seem unlikely 
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Fig. 1. Fractionation of the post-nuclear fraction from control (A) and X-ALD (B) cultured skin fibroblasts by isopycnic density gradient centrifu- 
gation. The distribution of subcellular organelles in the gradient was identified by their marker enzymes: catalase for peroxisomes, cytochrome c 
oxidase for mitochondria and NADPH cytochrome c reductase for endoplasmic reticulum. 
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that the function of ALD-P could be devoted to the 
import of only one protein (e.g. lignoceroyl-CoA ligase) 
because all other known functions of peroxisomes are 
normal in X-ALD. Secondly, based on what is known 
about the transport functions of ABC proteins [22], it 
also seems unlikely that ALD-P can import lignoceroyl- 
CoA ligase if lignoceroyl-CoA ligase is an integral 
membrane protein [28]. The ALD-P may rather serve a 
structural function necessary for the activity of ligno- 
ceroyl- CoA ligase, possibly as an anchor for the enzyme. 
Absence or a change in conformation of ALD-P in per- 
oxisomal membranes may influence the activity of ligno- 
ceroyl-CoA ligase. Both models raise an intriguing possi- 
bility, namely, the function of ALD-P may not only be 
limited to the transport or the activity of Iignoceroyl- 
CoA ligase. The definite function of ALD-P in per- 
oxisomal membranes will await the purification of ligno- 
ceroyl-CoA ligase. 
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Fig. 3. Immunoblot analysis of membrane and matrix components of 
purified peroxisomes with antibodies against ALD-P. Lanes 1 and 4 
represent molecular weight markers. Lanes 2 and 5 represent mem- 
brane and matrix proteins from control peroxisomes, and lanes 3 and 
6 represent membrane and matrix proteins from X-ALD peroxisomes. 
50 pg of protein was charged to each lane. 
kDa 
92.5 
69 
46 
30 
kDa 
12 3 4 5 6 7 8 9 10 111213 
14 15 16 17 18 19 20 21 22 23 24 
Fig. 2. Immunoblot analysis of subcellular organelles in fractions from 
control cultured skin fibroblast from a Nycodenz gradient with anti- 
bodies against ALD-P. 50 pug of proteins from each gradient fraction 
was resolved by electrophoresis and immunoblotted with antibodies 
against ALD-P. Lanes 1 and 14 are [‘4C]methylated molecular weight 
markers (ICN Biomedicals Inc.) Lanes 2-13 and 15-24 are gradient 
fractions protein as shown in Fig. 1. 
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